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cancer, and the general population, respectively (0 = worst; 52 =
least fatigue). Ten-year total per patient costs (drug, monitoring,
physician visits, adverse events) for managing GIST patients with
molecularly targeted treatment were estimated at £47,086–
£70,811 compared to £3674–£4230 with best supportive care.
CONCLUSIONS: Data suggest the incidence of GIST is similar
across countries; lower incidence in one study is likely explained
by differences in method of case ascertainment. Although
patients with GIST present with fatigue comparable to other
cancers, additional research is needed to comprehensively under-
stand its HRQL burden. The increased cost associated with new
therapies must be balanced against their expected beneﬁts.
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OBJECTIVES: To determine incidence and ﬁve years survival rate
of renal parenchyma tumours by TNM stage using cases recorded
in seven French departments cancer registries. To estimate overall
and with metastasis cancer prevalence, at the end of 2004, when
diagnosed over the period 2000–2004. METHODS: Identiﬁca-
tion of patients using the databases of seven cancer registries.
Data collected trough medical records and administrative data
(vital states). Assessment of raw global survival rate using Kaplan
Meier curves. Determination of global prevalence by summing
2000–2004 annual incident cases for which corresponding global
survival data have been applied. Same method for the estimation
of prevalence without metastases. Prevalence with metastases 
is global prevalence minus prevalence without metastases.
RESULTS: A total of 597 cases were identiﬁed and analized. 84%
of cases consisted of clear cell adenocarcinoma. Thus, the stan-
dardised levels of incidence (worldwide reference population) are
estimated to be 9.91 per 100,000 men and 3.75 per 100,000
women. Stages I, II, III and IV had speciﬁc incidences respectively
of 4.7, 1.1, 1.9 and 2.7 per 100,000 subjects. The 5 years sur-
vival rate in men and women was respectively 55% (CI95: 50–60)
and 65% (CI95: 58–71). Survival decreased with age and with
stage extension. The national number of cases is estimated to be
6,482 cases. Accordingly, the estimated partial global prevalence
is 29,300 cases, including 4,860 with metastasis (16.6%), this
rate increases with age: from 11% for patients aged less than 60
years to 29% for patients aged 80 years and over. CONCLU-
SIONS: This study is the ﬁrst one to give an estimation of spe-
ciﬁc parenchyma cancer by stage incidence, on a population base.
On this base, this study also provides prevalence estimations for
evolutive cancers.
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OBJECTIVE: Renal cell carcinoma has an asymptomatic course
and 25–30% of patients present with metastatic disease at time
of diagnosis. Molecularly targeted therapies (MTTs) represent a
breakthrough in treatment of mRCC, prolonging life, reducing
toxicity and the negative impact of treatment on health-related
quality of life (HRQOL), and offering viable therapeutic options
to a broader patient population relative to immunotherapy. The
objective of this study was to explore the burden of mRCC and
the potential clinical, economic and humanistic value of MTTs.
METHODS: PubMed, scientiﬁc meeting and online databases
were searched for articles relating to the epidemiologic, human-
istic and economic burden of mRCC. Thirty-ﬁve articles 
were selected. Epidemiology and economic statistics for mRCC
were estimated from international registries and published data
sources. RESULTS: Approximately 1500–8600 new mRCC
cases occur annually in major European and North American
countries, and Japan. Standard immunotherapy is largely inef-
fective (less than 10% response rates; no beneﬁt in most patients,
especially the elderly) despite a high annual cost of treatment
(e.g., $15,500–$82,000 across countries). In the absence of effec-
tive treatment, mRCC is rapidly fatal with 13% or fewer patients
surviving and a median survival of less than 1 year. Two-year
costs of care for mRCC have been estimated at $35,735/year
(US$). HRQOL of mRCC patients is comparable to congestive
heart failure, diabetes and other cancer patients and may be
further diminished by systemic immunotherapy. Recent studies
show that MTTs produce marked improvements in response
rates/survival, and tolerability without negative impact on
HRQL. CONCLUSIONS: The need for MTTs for mRCC is
characterized by the lack of effective treatment for the vast
majority of patients, high mortality, and considerable humanis-
tic and economic burden. Meaningful improvements in effec-
tiveness and tolerability in this patient population suggest that
MTTs offer economic and humanistic value in the treatment of
mRCC.
PCN4
A COMPARATIVE BUDGET IMPACT (BI) ANALYSIS OF
ARANESP® (DARBEPOETIN ALFA) 500 mG Q3W VERSUS
OTHER ERYTHROPOIESIS STIMULATING PROTEINS (ESP) IN
CHEMOTHERAPY-INDUCED ANEMIA (CIA) IN SPAIN
Pérez Alcántara F1, Badia X2,Arocho R3
1Health Outcomes Research, Barcelona, Spain, 2Health Outcomes
Research Europe, Barcelona, Spain, 3Amgen SA, Barcelona, Spain
ESP are standard treatment options for CIA. In this setting, both
Epoetin (EPO) alfa and EPObeta are administered three
times/week (TIW) or once/week (QW), while darbepoetin alfa
(DA) is the only ESP approved to be administered as once every
three weeks (Q3W). For ESP administered TIW or QW the SPCs
states to double the dose if hemoglobine increases <1 g/dL after
4 weeks. Doubling the dose is not needed with starting dose DA
500 μg Q3W. These administration differences might result in
different treatment costs for each agent. OBJECTIVE: Estimate
BI (mean cost/patient) of administering the different ESP in the
treatment of CIA in Spain. METHODS: The following variables
were considered in the economic model: ESP ex-manufacturer
price in Spain, administration pattern, weeks of treatment (12
weeks), weeks of evaluation before increments of dose (4 weeks),
dose increases, and overall cost of one administration (€59.72).
In addition, a two-way sensitivity analysis was performed to test
the robustness of the results, considering the following variables:
1) administration cost from a minimum of 0 to +25%, and 2)
the lowest and highest percentage of patients needing to increase
dose for EPOalfa and EPObeta from six studies found in the lit-
erature where this data was reported. RESULTS: In the base case
scenario, assuming an incidence of doubling the dose with both
EPOalfa and EPObeta of 29.60%, which was the mean value
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found in the literature (min 22.90%, max 42.80%), treatment
with starting dose DA 500 mg Q3W resulted in a BI that were
35.64% and 27.64% lower than EPOalfa 10,000 UI TIW and
40,000 UI QW respectively and 35.59% and 17.11% lower than
EPObeta 10,000 UI TIW and 30,000 UI QW respectively. The
results of the base case did not change in any of the sensitivity
scenarios. CONCLUSION: The model shows that treatment of
CIA with starting dose DA 500 mg Q3W is the rapeutic strategy
with lower mean cost per patient for all the analyzed scenarios
in Spain.
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OBJECTIVE: Development of a decision analytic model to esti-
mate the budget impact on the Swedish health service of using a
more effective diagnostic tool in conjunction with white light
cystoscopy (WLC) in the management of superﬁcial bladder
cancer (SBC). Hexvix (hexaminolevulinate) ﬂuorescence cys-
toscopy potentially allows more complete detection and delin-
eation of tumours compared with WLC in bladder cancer
diagnosis. METHODS: Model inputs, including procedure costs
and clinical algorithms, are based on the bladder cancer diag-
nosis and treatment guidelines of the European Association of
Urology (EAU), literature review and Swedish clinical practice.
Several trials report less residual tumour at early re-resection fol-
lowing 5-ALA ﬂuorescence-assisted TURB with 59% to 80% rel-
ative reduction in recurrence in the ﬂuorescence group compared
to WLC. Based on these ﬁndings, the model assumed a conser-
vative 40% reduction in recurrence rate when Hexvix was used
alongside WLC to guide TURB. The model projects the ﬂow of
all newly diagnosed SBC patients, following histological risk
classiﬁcation at ﬁrst TURB, through treatment one year after
diagnosis. It covers Hexvix use in the operating room to guide
ﬁrst TURB in all patients with suspicion of bladder cancer and
all follow-up TURBs in patients with recurrent SBC. RESULTS:
In the Swedish population of newly diagnosed bladder cancer
patients, the model projects a reduction in the number of pro-
cedures required in the ﬁrst year compared to WLC alone, i.e.
29 cystectomies and 1961 TURBs with Hexvix compared to 52
and 2141 with WLC. Avoidance of these procedures would
result in $212,895 (SEK 1,561,908) reduction in costs to the
Swedish health service the ﬁrst year after diagnosis. CONCLU-
SIONS: The model predicts that use of Hexvix as an adjunct to
WLC for all initial and follow-up TURBs in the ﬁrst year fol-
lowing diagnosis will result in substantial cost savings for the
Swedish health service.
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OBJECTIVES: Primary (ﬁrst-cycle) prophylaxis with ﬁlgrastim
or second generation pegﬁlgrastim has been recommended in the
2006 ASCO and EORTC clinical guidelines when the risk of
febrile neutropenia (FN) is >20%. Recent studies reported sig-
niﬁcantly greater reduction of FN with pegﬁlgrastim than with
ﬁlgrastim, yet no study has compared their cost-effectiveness.
The study purpose was to evaluate the cost-effectiveness of
primary prophylaxis with pegﬁlgrastim versus 11-day use of ﬁl-
grastim (as recommended) in women with stage I-III breast
cancer receiving chemotherapy with moderate to high risk of FN
in Spain. METHODS: We constructed a decision-analytic model
from a health care payer’s perspective. Costs included costs for
drugs, drug administration, FN-related hospitalizations and sub-
sequent care, and were based on ex-factory price listing and 
literature. Effectiveness was measured as FN avoided and life-
years-gained (LYG). FN risk (varied by days of ﬁlgrastim), FN
case-fatality, relative dose intensity (RDI), and the impact of RDI
on survival were based on a comprehensive literature review and
expert panel validation. Breast cancer mortality and all-cause
mortality were from national cancer registries and vital statistics
report. Sensitivity analyses were conducted on key variables.
RESULTS: In addition to being more effective, pegﬁlgrastim
primary prophylaxis produced an average cost-savings of €32
per patient (€4243 pegﬁlgrastim versus €4275 ﬁlgrastim). Pegﬁl-
grastim reduced the absolute risk of FN by 5.5% (12.5% versus
7%) and had a LYG of 0.06 (16.48 versus 16.42 years). Age of
diagnosis and cancer stage had minimal impact on the results.
Key inﬂuencing factors included drug costs, relative risk of FN,
and drug administration cost. CONCLUSION: Primary pro-
phylaxis with pegﬁlgrastim in Spain appeared not only to be
more effective but also cost-saving compared with ﬁlgrastim used
for 11 days per cycle.
PCN7
IMPACT OF CHANGES IN THE FINANCING OF THE HEALTH
SERVICES ON COSTS STRUCTURE ON THE EXAMPLE OF
CHEMOTHERAPY OF ADVANCED OVARIAN CANCER
Skowron A1, Pazdziora J2, Brandys J3
1Jagiellonian University, Cracow, Poland, 2The Beskid Center of
Oncology, Bielsko-Biala, Silesian region, Poland, 3Jagiellonian University,
Cracow, Malopolska, Poland
In 2002, the medical services in Poland has been paid by the inde-
pendent public insurance institutions—Regional Cash of Ills. In
2003 the government established The National Fund of Health,
which integrate all regional insurance institutions and provide
identical availability of medical services for every patient in
Poland. OBJECTIVES: To assess the impact of changes in ﬁnanc-
ing of health services on costs structure from the payer perspec-
tives on the example of advanced ovarian cancer. METHODS:
Two regimens of chemotherapy were assessed: cisplatin-
cyclophospamide (CC) and cisplatin-paclitaxel (CP). The data of
medical resources consumed were collected retrospectively in
two oncology centers in Poland. All medical care consumption
(diagnostic tests, hospitalization, ambulatory care and medica-
tions) were estimated from the patients’ chart. Costs were
derived from the hospitals’ Financial Departments for the year
2002. And from the system used by National Fund of Health for
2006. All cost were in polish zloty. RESULTS: The total cost of
chemotherapy per patient in CP group in 2002 were 21,658 zl
and in 2006—14,594 zl, while the standard chemotherapy with
CC scheme were 9008 zl in 2002 and 6000 zl in 2006. In CP
group in 2002 the 72,5% of the total cost were the cost of cyto-
statics, while in 2006 they decreased to 52.2%. In CC group the
main costs (56%) in 2002 were additional medications such as
antiemetics and GCSF, while in 2006—51% of total costs was
the cost of hospitalization. CONCLUSIONS: The changes in
ﬁnancing of the health system decreased the total costs of ovarian
cancer chemotherapy. The main reason of it in PC group could
